{"preliminary_commentary":{"by_channel":{"youtube":3,"x_thread":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pegylated interferon alfa-2a"]],"indication":"high-risk polycythemia vera and essential thrombocythemia","name":"MPD-RC 112","nct_id":"NCT01259856","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mpd-rc-112-nct01259856. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.","label":"PEGASYS","type":"EXPERIMENTAL"},{"description":"Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.","label":"Hydroxyurea","type":"ACTIVE_COMPARATOR"}],"collaborators":["Myeloproliferative Disorders-Research Consortium","National Cancer Institute (NCI)","Roche Pharma AG"],"completion_date":{"date":"2017-06-30","type":"ACTUAL"},"conditions":["High Risk Polycythemia Vera","High Risk Essential Thrombocythemia"],"enrollment":{"count":168,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"PEGASYS","otherNames":["Pegylated Interferon Alfa-2a"],"type":"DRUG"},{"name":"Hydroxyurea","otherNames":["Hydroxycarbamide"],"type":"DRUG"},{"name":"Aspirin","otherNames":["acetylsalicylic acid"],"type":"DRUG"}],"last_update":"2019-04-30","lead_sponsor":"Ronald Hoffman","official_title":"Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2017-06-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Complete Remission (CR)","timeFrame":"12 months"},{"measure":"Number of Participants With Partial Remission (PR)","timeFrame":"12 months"}],"references":[{"citation":"Thanarajasingam G, Bhatnagar V, Noble BN, Chen TY, Fiero MH, Hoffman R, Jeffery M, Mazza GL, Mascarenhas J, Mesa R, Murugappan M, Ross J, Sidana S, Warsame R, Kluetz PG, Dueck AC. Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies. BMC Med Res Methodol. 2025 Aug 7;25(1):189. doi: 10.1186/s12874-025-02617-y.","pmid":"40775758","type":"DERIVED"},{"citation":"Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, O'Connell CL, Kiladjian JJ, Mead AJ, Winton EF, Leibowitz DS, De Stefano V, Arcasoy MO, Kessler CM, Catchatourian R, Rondelli D, Silver RT, Bacigalupo A, Nagler A, Kremyanskaya M, Levine MF, Arango Ossa JE, McGovern E, Sandy L, Salama ME, Najfeld V, Tripodi J, Farnoud N, Penson AV, Weinberg RS, Price L, Goldberg JD, Barbui T, Marchioli R, Tognoni G, Rampal RK, Mesa RA, Dueck AC, Hoffman R. A randomized phase 3 trial of interferon-alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022 May 12;139(19):2931-2941. doi: 10.1182/blood.2021012743.","pmid":"35007321","type":"DERIVED"},{"citation":"Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428.","pmid":"31515250","type":"DERIVED"}],"start_date":{"date":"2011-09"},"study_type":"INTERVENTIONAL","title":"Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)","url":"https://clinicaltrials.gov/study/NCT01259856"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mpd-rc-112-nct01259856"}